Table 3.
SMAD4 immunoreactivity and genetic status of SMAD4 and TP53/cyclin dependent kinase inhibitor 2A (TP53-pathway) genes
| EAC_ID | SMAD4 loss (%) | SMAD4 mutations | TP53-pathway mutations (1 = yes) |
| EAC7 | 0 | — | 1 |
| EAC6 | 0 | — | 1 |
| EAC15 | 0 | — | 1 |
| EAC26 | 0 | — | 1 |
| EAC18 | 0 | — | 1 |
| EAC14 | 0 | — | 0 |
| EAC5 | 0 | — | 1 |
| EAC20 | 0 | — | 1 |
| EAC11 | 0 | — | 1 |
| EAC33 | 0 | — | 1 |
| EAC29 | 0 | — | 1 |
| EAC34 | 10 | — | 0 |
| EAC13 | 10 | — | 0 |
| EAC3 | 15 | — | 1 |
| EAC2 | 20 | — | 0 |
| EAC25 | 20 | — | 1 |
| EAC31 | 30 | — | 1 |
| EAC9 | 40 | — | 1 |
| EAC24 | 40 | — | 0 |
| EAC32 | 50 | — | 1 |
| EAC30 | 50 | — | 1 |
| EAC23 | 50 | p.R361C | 0 |
| EAC10 | 50 | — | 1 |
| EAC4 | 60 | — | 1 |
| EAC19 | 80 | — | 0 |
| EAC21 | 80 | — | 1 |
| EAC38 | 90 | — | 0 |
| EAC12 | 90 | p.S144* | 1 |
| EAC36 | 90 | — | 1 |
| EAC22 | 90 | — | 1 |
| EAC1 | 99 | — | 1 |
| EAC16 | 100 | — | 1 |
| EAC17 | 100 | p.G176* | 1 |
| EAC35 | 100 | — | 1 |
EAC, esophageal adenocarcinoma; SMAD4, SMAD family member 4; TP53, tumor protein 53.